AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25849358 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (anodal, 1.5 mA)
Number of subjects: 100
Study 25849358 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (control)
Number of subjects: 100
Study 22494086 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about breast cancer
Number of subjects: 120
Study 22494086 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about breast cancer trauma
Number of subjects: 120
Study 22494086 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about facts related to breast cancer
Number of subjects: 120
Study 22494086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no writing)
Number of subjects: 120
Study 22352083 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (10-session standardized school trauma intervention - Cognitive Behavioral Intervention for Trauma in Schools)
Number of subjects: 123
Study 18070731 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior hiatal repair
Number of subjects: 102
Study 18070731 — intervention group
Group type: COMPARATOR
Intervention: Posterior hiatal repair
Number of subjects: 102
Study 18070731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study 16854848 — intervention group
Group type: EXPERIMENTAL
Intervention: AVF blood-flow surveillance by ultrasound dilution (Qa surveillance group)
Number of subjects: 137
Study 16854848 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 137
Study 15251034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (75 mg BID)
Number of subjects: 33
Study 15251034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11878519 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension (CH) induced by sodium nitroprusside (mean arterial pressure (MAP) 50 mm Hg)
Number of subjects: 42
Study 11878519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of controlled hypotension (CH) and acute normovolaemic haemodilution (ANH) (post‐ANH haematocrit 29%; intraoperative MAP 50 mm Hg)
Number of subjects: 42
Study 11878519 — intervention group
Group type: COMPARATOR
Intervention: Standard anaesthesia (control)
Number of subjects: 42
Study 9061079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-compression ultrasound (9:1)
Number of subjects: 67
Study 9061079 — intervention group
Group type: EXPERIMENTAL
Intervention: High-compression ultrasound (15:1)
Number of subjects: 67
Study 9061079 — intervention group
Group type: COMPARATOR
Intervention: Uncompressed ultrasound
Number of subjects: 67
Study 8227787 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 61
Study 8227787 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 61
Study 2868824 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 2868824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 11
Study 2868824 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 11
Study 2868824 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 11
Study 2868824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29438121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B (Air Optix; Ciba Vision)
Number of subjects: 60
Study 29438121 — intervention group
Group type: COMPARATOR
Intervention: Comfilcon A (Biofinity; Coopervision)
Number of subjects: 60
Study 27867438 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 27
Study 27867438 — intervention group
Group type: COMPARATOR
Intervention: Normal Sleep (NS)
Number of subjects: 27
Study 24061546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined orthostatic hypotension criteria
Number of subjects: 8788
Study 24061546 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic orthostatic hypotension
Number of subjects: 8788
Study 24061546 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic orthostatic hypotension
Number of subjects: 8788
Study 22991208 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled reoxygenation CPB
Number of subjects: 49
Study 22991208 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxic/standard CPB
Number of subjects: 49
Study 22991208 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of hyperoxic/standard vs. controlled reoxygenation CPB
Number of subjects: 49
Study 20089558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg b.i.d.
Number of subjects: 55
Study 20089558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg b.i.d. in sarcopenic patients with BMI < 25 kg/m²
Number of subjects: 55
Study 20089558 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg b.i.d. in non-sarcopenic patients and/or overweight or obese
Number of subjects: 55
Study 20089558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 800 mg/day in sarcopenic male patients with BMI < 25 kg/m²
Number of subjects: 55
Study 20089558 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 800 mg/day in male patients above the cut-off for sarcopenia
Number of subjects: 55
Study 20089558 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 800 mg/day in male patients with BMI > 25
Number of subjects: 55
Study 18715214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor group (SG) - pump therapy with real-time continuous glucose monitoring (CGM)
Number of subjects: 146
Study 18715214 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - pump therapy and self-monitoring of blood glucose only
Number of subjects: 146
Study 18715214 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 146
Study 18715214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor group (SG)
Number of subjects: 146
Study 15757423 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril plus amlodipine (40/10 mg)
Number of subjects: 12600
Study 15757423 — intervention group
Group type: COMPARATOR
Intervention: Benazepril plus hydrochlorothiazide (40/25 mg)
Number of subjects: 12600
Study 12859086 — intervention group
Group type: EXPERIMENTAL
Intervention: Z100
Number of subjects: 38
Study 12859086 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Ray‐Posterior
Number of subjects: 38
Study 12859086 — intervention group
Group type: EXPERIMENTAL
Intervention: Prisma TPH
Number of subjects: 38
Study 12859086 — intervention group
Group type: EXPERIMENTAL
Intervention: All materials
Number of subjects: 38
Study 12859086 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed restorations
Number of subjects: 38
Study 10842904 — intervention group
Group type: EXPERIMENTAL
Intervention: Soapsuds enema
Number of subjects: 0
Study 10842904 — intervention group
Group type: COMPARATOR
Intervention: Tap water enema
Number of subjects: 0
Study 8874241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa (2.5 mg once daily)
Number of subjects: 320
Study 8874241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily)
Number of subjects: 320
Study 1847721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 12
Study 1847721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 12
Study 1847721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 12
Study 6198311 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Gy in 6 fractions over 3 weeks with 2 fractions per week
Number of subjects: 57
Study 6198311 — intervention group
Group type: COMPARATOR
Intervention: 10 Gy in 2 fractions with an interval of one week
Number of subjects: 57
Study 31902864 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan, vitamin B6, and nicotinamide-containing supplements
Number of subjects: 30
Study 31902864 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplements
Number of subjects: 30
Study 30081500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Magnesium (120 mg/day as magnesium aspartate)
Number of subjects: 37
Study 30081500 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine + Placebo
Number of subjects: 37
Study 30081500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Magnesium
Number of subjects: 37
Study 27372462 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 19
Study 27372462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 25113781 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6 MWT)
Number of subjects: 47
Study 21855289 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan added to dopamine
Number of subjects: 30
Study 21855289 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine added to dopamine
Number of subjects: 30
Study 19330561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 19330561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17785038 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (ccHRT) with estradiol valerate (E2V) and medroxyprogesterone acetate (MPA)
Number of subjects: 459
Study 16187809 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview (BMI)
Number of subjects: 64
Study 16187809 — intervention group
Group type: COMPARATOR
Intervention: Alcohol Education session (AE)
Number of subjects: 64
Study 16187809 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study 12482211 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg per os, evening assumption)
Number of subjects: 0
Study 12482211 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg bid per os)
Number of subjects: 0
Study 9665214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month high-intensity residential rehabilitation program
Number of subjects: 20
Study 9665214 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 9665214 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 20
Study 9665214 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study 7726479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam Hexetil (CTM) 200 mg bid
Number of subjects: 122
Study 7726479 — intervention group
Group type: COMPARATOR
Intervention: Cefixime (CX) 200 mg bid
Number of subjects: 122
Study 2572265 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol
Number of subjects: 14
Study 30937667 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated for Causation video
Number of subjects: 66
Study 30937667 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated in Sequence video
Number of subjects: 66
Study 30937667 — intervention group
Group type: COMPARATOR
Intervention: Procedural Only video
Number of subjects: 66
Study 30937667 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated instructional videos (both Integrated for Causation and Integrated in Sequence)
Number of subjects: 66
Study 28500081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction (BFR) training at 30% of 1 repetition maximum (1RM)
Number of subjects: 79
Study 28500081 — intervention group
Group type: COMPARATOR
Intervention: Standard quadriceps strengthening at 70% of 1 repetition maximum (1RM)
Number of subjects: 79
Study 28500081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction (BFR) training
Number of subjects: 79
Study 28500081 — intervention group
Group type: COMPARATOR
Intervention: Standard quadriceps strengthening
Number of subjects: 79
Study 26275779 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered Technetium Sulfur Colloid (fTcSC)
Number of subjects: 52
Study 26275779 — intervention group
Group type: COMPARATOR
Intervention: Technetium Tilmanocept (TcTM)
Number of subjects: 52
Study 24034570 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermally oxidized sunflower oil (TOSO)
Number of subjects: 20
Study 24034570 — intervention group
Group type: COMPARATOR
Intervention: Unheated sunflower oil (Control)
Number of subjects: 20
Study 22040589 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents Speak Up National Campaign (PSUNC)
Number of subjects: 0
Study 22040589 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19390842 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day contingent payment for smoking abstinence (14C)
Number of subjects: 34
Study 19390842 — intervention group
Group type: COMPARATOR
Intervention: 1-day contingent payment for smoking abstinence (1C)
Number of subjects: 34
Study 16958094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole monotherapy
Number of subjects: 0
Study 16958094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole with supplementary levodopa
Number of subjects: 0
Study 16958094 — intervention group
Group type: COMPARATOR
Intervention: Levodopa monotherapy
Number of subjects: 0
Study 15195032 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenoa repens (320 mg/die of Permixon) for at least 8 weeks before TURP
Number of subjects: 108
Study 15195032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medical treatment before intervention)
Number of subjects: 108
Study 12086556 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 2
Study 12086556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 9700993 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF-296 (0.3, 1.0, or 3.0 microg/kg/min)
Number of subjects: 24
Study 9700993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9700993 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF-296
Number of subjects: 24
Study 9700993 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF-296 (1.0 and 3.0 microg/kg/min)
Number of subjects: 24
Study 8024448 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sonography (LS)
Number of subjects: 100
Study 8024448 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative cholangiography (IOC)
Number of subjects: 100
Study 2601868 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of naproxene + 2 g of rosaprostol
Number of subjects: 22
Study 2601868 — intervention group
Group type: COMPARATOR
Intervention: 1 g of naproxene + placebo
Number of subjects: 22
Study 31831529 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 105
Study 31831529 — intervention group
Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 105
Study 29020783 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (Elonva) 100 µg for women younger than 36 years and less than 60 kg; 150 µg for women older than 36 years or heavier than 60 kg, combined with GnRH antagonists.
Number of subjects: 40
Study 29020783 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa and GnRH antagonists
Number of subjects: 40
Study 26162813 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Rehabilitation with 20 minutes of hot packs and 15 minutes of intermittent cervical traction three times/week for 6 weeks
Number of subjects: 60
Study 26162813 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Same rehabilitation as Group A plus ESWT (2000 impulses, 0.27 mJ/mm(2)) over the calcified NL guided by X-ray
Number of subjects: 60
Study 26162813 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Same treatment as Group B but ESWT guided by musculoskeletal sonography
Number of subjects: 60
Study 23569036 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional exercise plus proprioception and cognitive exercises
Number of subjects: 100
Study 23569036 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 100
Study 21495079 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT collaborative care
Number of subjects: 1801
Study 21495079 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study 19210062 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of persuasive arguments (seen once or twice)
Number of subjects: 0
Study 19210062 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater controlled processing (reflecting argument content)
Number of subjects: 0
Study 19210062 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater automatic influence of familiarity (reflecting repetition)
Number of subjects: 0
Study 19210062 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater controlled processing
Number of subjects: 0
Study 16713435 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, 80 mg/d
Number of subjects: 12
Study 16713435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15269144 — intervention group
Group type: EXPERIMENTAL
Intervention: BEC2 anti-idiotypic monoclonal antibody vaccine (25-microg dose)
Number of subjects: 24
Study 15269144 — intervention group
Group type: EXPERIMENTAL
Intervention: GD3-lactone-KLH (GD3-L-KLH) vaccine
Number of subjects: 24
Study 15269144 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall immunization with either vaccine
Number of subjects: 24
Study 15269144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular responses
Number of subjects: 24
Study 15269144 — intervention group
Group type: EXPERIMENTAL
Intervention: GD3-L-KLH vaccine
Number of subjects: 24
Study 15269144 — intervention group
Group type: EXPERIMENTAL
Intervention: BEC2 vaccine
Number of subjects: 24
Study 11137835 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 29
Study 9210011 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to a male confidant
Number of subjects: 75
Study 9210011 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to a female confidante
Number of subjects: 75
Study 9210011 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing the secret
Number of subjects: 75
Study 9210011 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between intimacy of disclosure and level of homophobia
Number of subjects: 75
Study 7962344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐estradiol combined with 2.5 mg dydrogesterone
Number of subjects: 165
Study 7962344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐estradiol combined with 5 mg dydrogesterone
Number of subjects: 165
Study 7962344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐estradiol combined with 10 mg dydrogesterone
Number of subjects: 165
Study 7962344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐estradiol combined with 15 mg dydrogesterone
Number of subjects: 165
Study 7962344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐estradiol combined with all doses of dydrogesterone
Number of subjects: 165
Study 31553374 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated and combined warm shower bath and perineal exercise with Swiss ball
Number of subjects: 128
Study 31553374 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm shower bath
Number of subjects: 128
Study 31553374 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal exercise with Swiss ball
Number of subjects: 128
Study 31553374 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined bath and ball
Number of subjects: 128
Study 28129748 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster rate of increase in milk feeds (30 ml/kg/day)
Number of subjects: 2800
Study 28129748 — intervention group
Group type: COMPARATOR
Intervention: Slower rate of increase in milk feeds (18 ml/kg/day)
Number of subjects: 2800
Study 25930719 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront zoledronic acid (ZA) 4 mg IV every 6 months
Number of subjects: 551
Study 25930719 — intervention group
Group type: COMPARATOR
Intervention: Delayed zoledronic acid (ZA) 4 mg IV every 6 months
Number of subjects: 551
Study 25930719 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront zoledronic acid (ZA)
Number of subjects: 551
Study 25930719 — intervention group
Group type: COMPARATOR
Intervention: Delayed zoledronic acid (ZA)
Number of subjects: 551
Study 22268726 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed 1064-nm Nd:YAG laser at 30 msec pulse width and fluence of 34 J/cm²; treated for three consecutive sessions at 4-week intervals.
Number of subjects: 18
Study 22268726 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral arm without treatment)
Number of subjects: 18
Study 21865084 — intervention group
Group type: EXPERIMENTAL
Intervention: cobas HPV test
Number of subjects: 41955
Study 21865084 — intervention group
Group type: COMPARATOR
Intervention: liquid-based cytology
Number of subjects: 41955
Study 21865084 — intervention group
Group type: EXPERIMENTAL
Intervention: cobas HPV test + liquid-based cytology
Number of subjects: 41955
Study 21865084 — intervention group
Group type: EXPERIMENTAL
Intervention: detection of HPV16, HPV18, or both
Number of subjects: 41955
Study 21865084 — intervention group
Group type: COMPARATOR
Intervention: ASC-US or worse cytology
Number of subjects: 41955
Study 21865084 — intervention group
Group type: EXPERIMENTAL
Intervention: detection of HPV16, HPV18, or both or low-grade squamous intraepithelial lesion or worse cytology
Number of subjects: 41955
Study 21865084 — intervention group
Group type: EXPERIMENTAL
Intervention: detection of HPV16, HPV18, or both or high-grade squamous intraepithelial lesion or worse cytology
Number of subjects: 41955
Study 18648895 — intervention group
Group type: EXPERIMENTAL
Intervention: On‐Q pump systems filled with 0.375% bupivacaine
Number of subjects: 30
Study 18648895 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 30
Study 16566936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis during embryo transfer (ET)
Number of subjects: 194
Study 16566936 — intervention group
Group type: COMPARATOR
Intervention: Regular IVF/ET cycles (Control)
Number of subjects: 194
Study 14520284 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of flunitrazepam (F0.25 group)
Number of subjects: 75
Study 14520284 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of flunitrazepam (F0.5 group)
Number of subjects: 75
Study 14520284 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 75